ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
11 announcements
Indegene Limited hosted its Indegene Digital Summit 2026, focusing on operationalizing AI within life sciences. The event also featured the presentation of the VITAL Awards 2026.
Indegene Limited completed the internal merger of its two indirect wholly owned subsidiaries in Germany. This reorganization does not impact Indegene's financial position or operations.
Indegene delivered its strongest Q1 growth in four years, yet remains burdened by elevated costs from strategic investments and workforce transformation.
Indegene reported Q1'FY27 revenue of ₹10,631M (+39.7% YoY) with an EBITDA margin of 16.9%. The strategy focuses on scaling GenAI-powered solutions and deepening engagement with large pharma.
Indegene Ltd reported revenue from operations of ₹1,063 Cr (+39.7% YoY) and net profit of ₹116.2 Cr (-0.2% YoY) for Q1 FY27.
Indegene reported FY26 revenue of INR 35,105M with 19.4% adjusted EBITDA margin, positioning itself as an AI-embedded specialist displacing traditional agencies and CROs in life sciences.
Indegene positions as an AI-embedded operating partner for life sciences. Reported FY26 revenue of INR 35.1Bn with 19.4% EBITDA margins and 29.4% CAGR.
Indegene crossed ₹1,000Cr quarterly revenue milestone in Q4FY26. Strategy focuses on GenAI-led transformation (Tectonic model) and deepening top-20 global pharma relationships.
Indegene crossed the ₹1000cr quarterly revenue milestone for the first time in Q4FY26, though PAT was slightly dragged by exceptional legal provisions.
Indegene delivered strong FY26 revenue of INR 35,105M (+23.6% YoY) with steady 19.4% EBITDA margins, driven by GenAI-led transformation in life sciences.
Indegene Ltd reported revenue from operations of ₹1,003 Cr (+32.8% YoY) and net profit of ₹79.7 Cr (-32.2% YoY) for Q4 FY26.